Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968809 · ClinicalTrials.gov registry record
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 101
- Enrollment target
NCT03968809 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 101 participants.
The verdict
NCT03968809 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.
Interventions
- DIAGNOSTIC_TEST CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2020-06-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03968809
The ClinicalTrials.gov registry entry for NCT03968809 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetesis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT03968809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03968809 about?
NCT03968809 is a clinical study titled "Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes". This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.
What is the current status of trial NCT03968809?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2019-09-05. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03968809?
The interventions under investigation include: CardioFlux Magnetocardiography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03968809?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.